NEWS

Biomed Industries to Present NA-931 Phase 2 Results Showing Significant Weight Loss and Preliminary Evidence of Lean-Mass Preservation at ObesityWeek 2026

Investigational oral quadruple receptor agonist achieved 13.8% mean weight loss at 13 weeks; preliminary body-composition findings support further evaluation.

SAN JOSE, CA, UNITED STATES, November 11, 2026 — — Biomed Industries, Inc. (“Biomed”) announced that Lloyd L. Tran, PhD, Chairman and Chief Executive Officer, will present Phase 2 clinical results for NA-931, its investigational oral, once-daily obesity treatment, at ObesityWeek, November 14-17, 2026 in Washington, DC.

The oral presentation, titled “Phase 2 Study of NA-931, a Quadruple Receptor Agonist, Demonstrates Significant Weight Loss and Preservation of Lean Mass,” will highlight dose-dependent weight reduction, gastrointestinal tolerability, and preliminary body-composition findings. Coauthors include Fern D. Vu, Zung V. Tran, Jennifer Thompson, and David Nguyen.

NA-931 is an investigational small molecule targeting four receptors: insulin-like growth factor-1 (IGF-1), glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon. Biomed is investigating whether this combination of receptor activities can support meaningful weight reduction while limiting lean-mass loss.

Phase 2 Results: Dose-Dependent Weight Reduction

The 13-week, multicenter, randomized, double-blind, placebo-controlled Phase 2 study enrolled 125 adults with obesity or overweight and weight-related comorbidities. Participants received NA-931 at 60, 90, 120, or 150 mg once daily, or placebo.

Key findings included:

• 13.8% mean body-weight reduction in the 150 mg group, compared with 1.9% with placebo, representing an 11.9-percentage-point placebo-adjusted difference (p=0.001).
• 11.3% mean body-weight reduction in the 120 mg group, representing a 9.4-percentage-point placebo-adjusted difference (p=0.002).
• Mean body-weight reductions of 5.5% and 8.7% in the 60 mg and 90 mg groups, respectively.

Among the 96 participants receiving NA-931, pooled rates of reported gastrointestinal adverse events were 7.3% for nausea, 5.2% for vomiting, and 6.3% for diarrhea. All reported nausea was mild, and no constipation was reported.

Why Lean-Mass Preservation Matters

Preserving lean mass is an important consideration in weight management, particularly for older adults. Skeletal muscle supports strength, mobility, glucose regulation, and everyday physical function. Published estimates suggest that muscle mass declines by approximately 3–8% per decade after age 30, with faster declines after age 60. Weight loss can further reduce lean tissue: across selected weight-loss studies, lean-mass reductions have represented approximately 15–40% of total weight lost, although estimates vary by treatment, population, and measurement method. These findings underscore the importance of assessing body composition alongside weight reduction.

Preliminary Body-Composition Findings

The presentation reported a 1.7% reduction in lean mass over 13 weeks with NA-931, alongside an 11.9-percentage-point placebo-adjusted reduction in body weight. For context, published findings from separate studies reported 14.9% weight loss and 13.2% lean-mass reduction with semaglutide over 68 weeks, and 20.9% weight loss and 10.9% lean-mass reduction with tirzepatide over 72 weeks. Body composition was assessed using dual-energy X-ray absorptiometry (DXA/DEXA).

DXA estimates lean soft tissue, including skeletal muscle, organs, and water; changes in DXA-measured lean mass do not directly establish changes in skeletal muscle or muscle function.

“Meaningful weight loss and preservation of lean mass are important goals in obesity treatment,” said Dr. Tran. “These Phase 2 findings support advancing NA-931 into Phase 3 evaluation and further investigating whether its quadruple receptor activity can help address both goals.”

Scientific Rationale and Phase 3 Development

Dr. Tran’s presentation will discuss the rationale for combining metabolic receptor activity with IGF-1 receptor signaling, including its role in muscle maintenance. The presentation will also place NA-931’s development within Biomed’s broader research framework examining shared mechanisms across metabolic, neurological, and cardiovascular diseases.

Biomed is advancing NA-931 toward Phase 3 clinical evaluation, with a focus on sustained weight reduction, longer-term safety and tolerability, and further assessment of body composition. NA-931 remains investigational and has not been approved for commercial use.

About Biomed Industries, Inc.

Biomed Industries, Inc. is a biopharmaceutical company developing investigational therapies for neurological, metabolic, and rare diseases. Its pipeline includes NA-831 for Alzheimer’s disease, NA-921 for Rett syndrome, NA-931 for obesity, and NA-911 for stroke. For more information, visit www.biomedind.com.

About BiomedAI, Inc.

BiomedAI, Inc., a subsidiary of Biomed Industries, applies artificial intelligence to drug discovery, drug repurposing, and predictive medicine. Its research integrates computational analysis with biological and clinical evidence to guide therapeutic development. For more information, visit www.biomedai.com.

Media Enquiries

David Lee
Biomed Industries, Inc.
Tel. 1-800-824-5135
media@biomedind.com

Forward-Looking Statements

This release contains forward-looking statements concerning research programs, therapeutic potential, and development plans. Actual results may differ materially because of scientific, clinical, regulatory, and other uncertainties. The therapeutic candidates discussed are investigational for the indications described.


For more news, please visit our News page.

For further information about Biomed Industries, Inc., please contact us.